| Minocycline Hydrochloride | Vyne pharma | ||
| 4%, Foam , Aerosol |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
Less Than 5
|
None | ||
| None | None | ||
| AMZEEQ is indicated for the topical treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older. | |||
|
Yes
| |||
| Amzeeq | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* | ******* |
| ******* ************ ************ | **********-**** *****-**** ******** ************, ********* ***** *** **** *** ***** **** | ******* ************ ************ | ************, **** *** ***** **** ******** ********** *** **** ******* | ************ *** ******* *** ******** ******* *** **** | ****** *** ******* ** ** ******** **** ****** ******* ******** | ************, **** *** ***** **** ******** ********** *** **** ******* | ************ *** ******* *** ******** ******* *** **** | ******* ************ ************ | **********-**** *****-**** ******** ************, ********* ***** *** **** *** ***** **** | ******* ************ ************ | ******* ************ ************ |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ******* | *** \ ********* | *** **, **** | ******* | **** | ** **** *, **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|